WuXi AppTec stock
Price history
+54.02% over the period1 year: from ¥93.76 (November 17, 2025) to ¥144.41 (November 16, 2026), +54.02%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ¥144.41 |
| October 30, 2026 | ¥142.01 |
| September 30, 2026 | ¥167.34 |
| August 31, 2026 | ¥154.78 |
| July 31, 2026 | ¥128.43 |
| June 30, 2026 | ¥124.51 |
| May 29, 2026 | ¥101.60 |
| April 30, 2026 | ¥109.55 |
| March 31, 2026 | ¥98.10 |
| February 27, 2026 | ¥98.01 |
| January 30, 2026 | ¥95.20 |
| December 31, 2025 | ¥90.64 |
| November 28, 2025 | ¥91.19 |
| November 17, 2025 | ¥93.76 |
At a glance
The company
Provides contract research, development and manufacturing services for small molecule drugs and biology solutions across discovery, development and clinical stages
Latest results
Quarter to September 30, 2026 · EPS ¥2.74 (estimate ¥2.55)
Next event
TickerLandia's take on WuXi AppTec
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 23 vs a median of 31 over its last 8 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 16 vs 37 (−56%) in a group of 10.
- Strong point: Financial strength (94/100 in its group). Weak point: Earnings stability (39/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−16.81% from the 52-week high
Analysts · 22 analysts
Average target¥202.34+40.11% vs. price
Buy 22 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: WuXi AppTec
Compared with similar companies: very high financial strength, very strong momentum, and very high profitability.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricelow35
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 13.0 26 Forward P/E 14.4 10 P/E (trailing 12 months) 16.3 10 Price/book 4.36 52 Price/sales 7.91 76 Profitabilityvery high83
How much it earns on revenue and capital.
Metric Value Position in group Net margin 47.2% 98 ROE 30.0% 80 ROA 14.3% 87 Operating margin 44.8% 98 Gross margin 54.5% 50 Earnings stabilitylow39
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 7.4% 17 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthvery high81
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +38.00% 94 Earnings growth (year over year) +127.70% 94 Average revenue growth (3 years) +3.33% 54 Financial strengthvery high94
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.09 91 Current ratio 3.43 94 Interest coverage 53.7 94 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −1.66 98 Dividendaverage43
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 23.3% 22 Dividend yield 1.4% 70 Consecutive dividend years 8 years 38 Market momentumvery strong89
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +51.67% 87 Distance from 200-day average +20.11% 91 Risklow38
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 19.5% 15 Volatility (60 days) 43.2% 62
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
WuXi AppTec is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), WuXi AppTec's P/E today is 23.5, below the median of its last 8 fiscal years (31.3; between 14.7 and 106.9 from 2018 to 2025). WuXi AppTec's P/E (trailing 12 months): 16.3, −56% against the median of a group of 10 similar companies (36.9).
Compared with 10 similar companies
| Metric | WuXi AppTec | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 16.3 | Low | |
| Forward P/E | 14.4 | Low | |
| Operating margin | 44.8% | High | |
| ROE | 30.0% | High | |
| Debt/equity | 0.09 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: WuXi AppTec. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥16.64B
Latest quarter · Q3 2026
Net income
¥8.28B
Latest quarter · Q3 2026
Quarterly net margin
49.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥444.01B
- P/E
- 16.3
- EPS
- ¥8.95
- Volume
- 27.67M
- Daily trading
- €848.12M
- Dividend yield
- 0.35%
- Last ex-dividend on September 4, 2026
How WuXi AppTec is changing
All resultsRevenue grew 21.3% a year on average over the last 5 years
Operating margin rose from 23.2% to 37.9%
Free cash flow equal to 73% of net income
Returns
WuXi AppTec returns with dividends
¥1,000 invested in WuXi AppTec 5 years ago, on November 16, 2021, would be worth ¥1,153 today with dividends reinvested: +15.29% in total, +2.89% per year. On price alone it would be ¥1,058 (+5.81%).
| Period | WuXi AppTec | ¥1,000 becomes |
|---|---|---|
| 1 month | +0.08% | ¥1,001 |
| 6 months | +40.03% | ¥1,400 |
| Year to date | +59.32% | ¥1,593 |
| 1 year | +56.93% | ¥1,569 |
| 3 years | +80.90% | ¥1,809 |
| 5 years | +15.29% | ¥1,153 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
WuXi AppTec: technical analysis
WuXi AppTec shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 14.0% below its all-time closing high (¥168.00, July 1, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 45
- Between 30 and 70
- vs 200-session average
- +18.36%
Support and resistance
Price areas where WuXi AppTec has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥172.40+19.38%2 touches, last on September 22, 2026
- Resistance¥149.96+3.84%2 touches, last on September 11, 2026
- Last price¥144.41
- Support¥135.53−6.15%2 touches, last on October 23, 2026
- Support¥130.52−9.61%2 touches, last on November 3, 2026
- Support¥114.80−20.51%4 touches, last on July 20, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 43.1%
- Largest fall in the last year
- −19.46%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
WuXi AppTec: seasonality
Average monthly price change over 9 years
Over the last 9 years, the strongest month for WuXi AppTec has been July: +6.46% on average, positive in 6 years out of 9. The weakest has been November: −4.15% on average, positive in 2 years out of 8.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.49% | +2.44% | 6 of 8 |
| February | +2.22% | +1.73% | 5 of 8 |
| March | −1.68% | −1.17% | 4 of 8 |
| April | −1.16% | −5.66% | 3 of 8 |
| May | −1.90% | −3.66% | 3 of 8 |
| June | +5.79% | +9.44% | 6 of 9 |
| July | +6.46% | +4.97% | 6 of 9 |
| August | +5.88% | +4.10% | 5 of 9 |
| September | +5.87% | +8.11% | 6 of 9 |
| October | −1.79% | −0.69% | 4 of 9 |
| November | −4.15% | −5.49% | 2 of 8 |
| December | +1.55% | +1.62% | 4 of 8 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
WuXi AppTec and its competitors
With revenue of CNY 43.4 billion in the fiscal year ended December 2025, WuXi AppTec Co., Ltd. operates as an investment holding company whose businesses span drug discovery, development and manufacturing. Its contract research, development and manufacturing services cover small molecules, oligonucleotides, peptides and complex conjugates, from discovery through to commercial production, and include biology services that run from target discovery to candidate selection and clinical entry.
- Headquarters
- Shanghai, China
- Employees
- 33,834
- Founded
- 2000
- Chief executive
- Ge Li
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| WuXi AppTec603259 | $66.55B | 44.8% | 16.3 | +40.03% |
| WuXi XDC Cayman2268 | $11.19B | 28.1% | 56.4 | +24.45% |
| Sonic HealthcareSHL | $6.67B | 9.3% | 16.2 | +6.67% |
| IDEXX LaboratoriesIDXX | $55.48B | 32.5% | 47.0 | +33.21% |
| Lonza GroupLONN | $55.48B | 23.5% | 44.1 | +43.25% |
| Agilent TechnologiesA | $49.04B | 24.5% | 34.3 | +54.30% |
Same industry or related industries, similar size. Compare WuXi AppTec with its competitors · Full profile
